Summary
A multicenter cooperative study was conducted to evaluate the clinical efficacy and safety ofcis-diammine(glycolato)platinum (254-S), a second-generation anticancer platinum complex, in the treatment of genitourinary cancers. 254-S was given i. v. at 100 mg/m2 at 4-week intervals. As a result, 2 complete responses (CRs) and 8 partial responses (PRs) were obtained in 35 patients with transitional-cell carcinoma (TCC) of the urinary bladder or pyeloureter, 3 PRs were obtained in 16 subjects with prostatic cancer, and 6 CRs and 6 PRs were obtained in 15 patients with testicular cancer, generating objective response rates of 28.6% [95% confidence interval (CI), 14.6%–46.3%], 18.8% (95% CI, 4.0%–45.6%), and 80.0% (95% CI, 51.9%–95.7%), respectively. Bone marrow suppression was the dose-limiting toxicity, although it was reversible. Although no hydration was performed in approx. 40% of the patients, the incidence of nephrotoxic effects was low and most of those encountered were mild, the exception being one patient who showed severe renal insufficiency after the first treatment. Nausea and vomiting occurred in approx. 70% of the patients, but most gastrointestinal toxicities were controlled without antiemetic treatment. In addition, liver-function impairment was rarely observed. We conclude that 254-S is a promising cisplatin analogue for the treatment of genitourinary cancers and is worthy of further investigation in large-scale, randomized comparative studies with other platinum derivatives in both single-agent and combination regimens.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akaza H, Isurugi K, Oishi Y, Kitajima K, Sawamura Y, Baba S, Yoshida K, Otani M, Harada M, Gunji A, Aso Y, Niijima T (1988) A prospective, randomized controlled study on the treatment of stage C and D prostatic cancer with Estracyt in combination with chemotherapeutic agents. Jpn J Clin Oncol 18:343–355
Akaza H, Hagiwara M, Deguchi N, Kawai T, Satomi Y, Matsuda T, Miki T, Ueda T, Kotake T, Tazaki H, Aso Y, Niijima T (1989) Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 23:181–185
Einhorn LH (1990) Treatment of testicular cancer: a review and improved model. J Clin Oncol 8:1777–1781
Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N (1990) Phase II study of (glycolato-O,O′)-diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26:393–396
Inuyama M, Miyake H, Ohta K (1989) Phase II study of 254-S for head and neck cancer. J Jpn Soc Cancer Ther 24:2192
Japanese Urological Association and Japanese Society of Pathology (1992) Response criteria for urogenital cancer treatment, 1991. Jpn J Urol 83:447–472
Kato T, Noda K, Terashima Y, Hirabayashi K, Nishimura H (1989) Phase II study ofcis-diammine(glycolato)platinum (254-S), a new platinum complex, for gynecological malignancy. In: Rubenstein E, Adam D (eds) Recent advances in chemotherapy (anticancer section). Proceedings of the 16th International Congress of Chemotherapy. Lewin-Epstein, Jerusalem, pp 823.1–823.5
Niijima T, Tazaki H (1988) Phase II study of carboplatin for genitourinary cancer. Jpn J Cancer Chemother 14:2305–2311
Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S, Minato K, Nakagawa K, Saijo N (1989) Pharmacokinetics of (glycolato-O,O′)diammineplatinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243–246
Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N (1991) Phase I study and pharmacological analyses ofcis-diammine(glycolato)platinum (254-S; NSC375101D) administered by 5-day continous intravenous infusion. Cancer Res 52:1472–1477
Shiratori O, Kanai H, Uchida N, Takeda Y, Totani T, Sato K (1985) Antitumor activity of 254-S, a platinum complex, in the rodent. In: Ishigami J (ed) Recent advances in chemotherapy. University of Tokyo Press, Tokyo, p 635
Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Wiselberg LR, Rosado K, Smart T, Lin SY, Penenberg D, Fair WR, Whitmore WF Jr (1989) Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448–2458
Totani T, Aono K, Komura M, Adachi Y (1986) Synthesis of (glycolato-O,O′)diammineplatinum(II) and its related complexes. Chem Lett: 429
Totani T, Asano K, Adachi Y, Komura M, Shiratori O, Sato K (1987) Bidentrate hydroxycarboxylic acid platinum (II) complex with antitumor activity. In: Nicolini M (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Martinus Nijhoff, Boston, p 744
WHO (1979) Handbook for reporting results of cancer treatment Offset publication 48. WHO, Geneva
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Akaza, H., Togashi, M., Nishio, Y. et al. Phase II study ofcis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother. Pharmacol. 31, 187–192 (1992). https://doi.org/10.1007/BF00685546
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685546